Page last updated: 2024-11-05

thalidomide and Papulosquamous Disorders

thalidomide has been researched along with Papulosquamous Disorders in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Yin, X1
Huang, C1
Feng, Y1
Xia, J1
Zhang, M1
Yin, Z1
Grape, J1
Frosch, P1

Other Studies

2 other studies available for thalidomide and Papulosquamous Disorders

ArticleYear
Apremilast for the treatment of papuloerythroderma of Ofuji.
    Clinical and experimental dermatology, 2023, 10-25, Volume: 48, Issue:11

    Topics: Dermatitis, Exfoliative; Humans; Skin Diseases, Papulosquamous; Thalidomide

2023
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2011, Volume: 62, Issue:8

    Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide

2011